Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-1182
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice ; day:16 ; month:10 ; year:2018 ; pages:1-14
Molecular neurobiology ; (16.10.2018), 1-14
- Urheber
-
Fuente, Sandra de la
- Beteiligte Personen und Organisationen
-
Sansa, Alba
Periyakaruppiah, Ambika
Garcera, Ana
Soler, Rosa M.
SpringerLink (Online service)
- DOI
-
10.1007/s12035-018-1379-z
- URN
-
urn:nbn:de:101:1-2018112200410454513726
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fuente, Sandra de la
- Sansa, Alba
- Periyakaruppiah, Ambika
- Garcera, Ana
- Soler, Rosa M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy
Spinal muscular atrophy
Spinal Muscular Atrophy autophagy profile is tissue-dependent: differential regulation between muscle and motoneurons
Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology
Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes
Dynamic remodeling of endoplasmic reticulum and ribosomes in axon terminals of wildtype and Spinal Muscular Atrophy motoneurons
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds
Modeling morphological changes in spinal motoneurons following spinal cord injury to explore changes in electrical behavior
Very severe spinal muscular atrophy (Type 0)
The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran
Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy
Spinal muscular atrophy
Spinal Muscular Atrophy autophagy profile is tissue-dependent: differential regulation between muscle and motoneurons
Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology
Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes
Dynamic remodeling of endoplasmic reticulum and ribosomes in axon terminals of wildtype and Spinal Muscular Atrophy motoneurons
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds
Modeling morphological changes in spinal motoneurons following spinal cord injury to explore changes in electrical behavior
Very severe spinal muscular atrophy (Type 0)
The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran
Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy
Spinal muscular atrophy
Spinal Muscular Atrophy autophagy profile is tissue-dependent: differential regulation between muscle and motoneurons
Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology
Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes
Dynamic remodeling of endoplasmic reticulum and ribosomes in axon terminals of wildtype and Spinal Muscular Atrophy motoneurons
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds
Modeling morphological changes in spinal motoneurons following spinal cord injury to explore changes in electrical behavior
Very severe spinal muscular atrophy (Type 0)
The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran